Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$10.1M
2M shares
52-week range
$4.21 – $23.25
21% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
www.lexariabioscience.comNo one on the platform currently holds LEXX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 16,300 | $12.7K |
| Execution date | Ratio |
|---|---|
| 2026-08-03 | 1-for-15reverse |
No one on the platform has traded LEXX yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $20000 | -97.0% | $-4.05 | $-4.05–$-4.05 | — | 1 |
| 2027 | $1M | +6915.0% | $-4.65 | $-4.65–$-4.65 | — | 1 |
| 2028 | $2M | +13.0% | $-4.20 | $-4.20–$-4.20 | — | 1 |
| 2029 | $70M | +4328.1% | $20.10 | $20.10–$20.10 | 0.4× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-13 | $-0.90 | $-1.20 | -33.3% |
| 2026-04-13 | $-1.05 | $-0.90 | +14.3% |
| 2026-01-13 | $-1.95 | $-1.05 | +46.2% |
| 2025-11-26 | $-2.40 | $-2.10 | +12.5% |
| 2025-07-14 | $-2.25 | $-3.15 | -40.0% |
| 2025-04-14 | $-2.40 | $-2.25 | +6.2% |
| 2025-01-10 | $-1.80 | $-2.40 | -33.3% |
| 2024-11-26 | $-1.65 |
| $-2.25 |
| -36.4% |
| $67M |
| — |
| CLSDClearside Biomedical, Inc. | $0.41 | +0.00% | $2M | — |
| CRISCuris, Inc. | $1.87 | +11.98% | $4M | — |
Source: Financial Modeling Prep · peers by sector/industry
$LEXX More info on our new partner… PegBio (PegBio Co., Ltd.) is a publicly traded biopharmaceutical company founded in 2008 and based in Hangzhou, China. It focuses on discovering and developing long-acting therapeutic drugs for metabolic and chronic conditions like type-2 diabetes and obesity using specialized PEGylation technology. Key Products and PipelinePB-119 (Visepegenatide): A long-acting GLP-1 receptor agonist designed for once-weekly diabetes management, which gained approval and commercialization in China. Other Candidates: The company develops additional pipeline assets—such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309—targeting obesity, diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Recent Partnerships: PegBio entered a material transfer agreement with Lexaria Bioscience to evaluate oral delivery applications using DehydraTECH technology for proprietary GLP-1 molecules. $LLY $NVO $PFE $AMGN
View on StockTwits ↗$LEXX Buying as we speak. You may just get your $44 Purenergy
View on StockTwits ↗$LEXX $LLY $NVO $RANI $VKTX Almost impossible to print a candle like that without a strong green follow-through... Today and Monday are going to be fun 📈 Management has positioned us for an epic catalyst ladder over the next ~30 days. Still thrilled with the team securing our first commercial validation for our oral GLP-1 delivery tech—exciting times ahead 💰 Just imagine what happens when we officially execute a commercial deal with the multi-billion dollar Pharma giant we've been collaborating with for two years now... 🔥 BOOM 💥 🧨 📈 💰 https://investingnews.com/lexaria-enters-a-material-transfer-agreement-with-pegbio/
View on StockTwits ↗$LEXX Setting up for an epic short squeeze on the back of a commercial pharma MTA validation and GLP-1 data drops any day.. Float is only 1.6m shares. Could be an epic squeeze Monday as institutional capital can buy again as the Nasdaq non-compliance comes off 📈 BOOM FUCKING BOOM 💥 🤯
View on StockTwits ↗$LEXX $LLY $NVO $RANI $VKTX They tryna everything they can to hide the facts but it’s too late 🧨 Lexaria is blowing up 🔥
View on StockTwits ↗$LEXX Sounds like some scared shorts heading into tomorrow 🥶 📈 🧨 💰
View on StockTwits ↗$LEXX Yeah…pick me up at $44. Fuck you Lexx. I put my money in when you should have managed the company better. All these companies are just retail robbing machines. We got robbed. When’s the next split?
View on StockTwits ↗$LEXX 🔥 MASSIVE BREAKOUT! $LEXX crushed the chart today, closing up +32.35% at $8.10 on over 92K shares traded! The execution of a second independent GLP-1 MTA with commercial-stage biopharma PegBio proves DehydraTECH isn't a one-partner pony—it's a global platform. With the micro-float officially ignited, the chart just printed a textbook high-volume engulfing breakout right off the $6.00 floor. 🚀 NEXT CATALYSTS IN SIGHT: Monday: Nasdaq Compliance Notice: Clearing 10 consecutive days >$1.00 following the 1-for-15 split. Institutional capital will start flowing again. Human Study #7 Readout: Top-line 5-week steady-state PK & Wegovy head-to-head data (late Aug/Sept). Animal Study #1 Results: Concurrent GLP-1 readout dropping alongside human data. Shorts are trapped, volume is surging, and the runway is clear! 📈🚀 $LLY $NVO $VKTX $RANI @topstockalerts @MrHamilton @TopGunFP
View on StockTwits ↗$LEXX Got a long way to go. The math is easy $15 equals $1 pre-split. 
View on StockTwits ↗$LEXX Incredible to be buying this at a 12m mkt cap… The day we’ve all been waiting for folks. Official commercial validation of this platform and execution on the companies multi-pronged MTA strategy. Based on all the research I’ve done this should now be trading at a $30-$40 million market cap at a minimum!!! Good times ahead!!!
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.